© 1999 by European Society of Cardiology
Incidence and clinical significance of transformation of atrial fibrillation to atrial flutter in patients undergoing long-term antiarrhythmic drug treatment
Istituto di Cardiologia dell'Università degli Studi, CNR, Centro Cardiologico Fondazione ‘Monzino’, IRCCS Milan, Italy
AIMS: To investigate the rate of transformation of atrial fibrillation to atrial flutter in patients taking antiarrhythmic drugs for the prophylaxis of atrial fibrillation, we retrospectively analysed data from 305 consecutive patients with paroxysmal atrial fibrillation (155 male; mean age 63±11 years) treated with ventricular rate controlling drugs, antiarrhythmic drugs, or without drugs.
METHODS AND RESULTS: At a mean follow-up of 9 months (range 1–24) all patients experienced recurrence of arrhythmia: 48 (14·6%, Group A) suffered Type 1 atrial flutter, and 257 (85·4%, Group B) atrial fibrillation. The relative rate of recurrence of atrial flutter vs atrial fibrillation was similar in patients without treatment or with ventricular rate controlling drugs (from 6·8% to 14·6%, P=ns). However, recurrence was higher (25%) in patients administered antiarrhythmic drug therapy. The relative risk in these patients was 3·02 times greater, compared with patients without treatment, or treated with rate controlling drugs (P<0·001). There were no differences between groups concerning the baseline clinical characteristics and the clinical consequences of the recurrence; patients with atrial flutter had a lower rate of conversion to sinus rhythm (42% vs 64%) and a higher rate of hospital admission (69% vs 36%) compared with those with atrial fibrillation. Six patients (8·5%) experienced 1:1 atrioventricular conduction during atrial flutter with a ventricular rate of 240–280 beats.min–1.
CONCLUSION: Our data suggest that the use of antiarrhythmic drugs for the prophylaxis of atrial fibrillation is associated with a threefold increase in the probability of Type 1 atrial flutter recurrence, as opposed to atrial fibrillation, which may have important clinical consequences, but which did not in our study.
Key Words: Atrial fibrillation, atrial flutter, antiarrhythmic drug treatment
Correspondence: Dr Stefania Riva, Centro Cardiologico, via C. Parea 4, 20138 Milan, Italy.
[1] Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation-an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48: 345–371.[Web of Science][Medline]
[2] Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–1022.[Abstract]
[3] Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a metaanalysis of randomized control trials. Circulation 1990; 82: 1106–1116.
[4] Falk RH. Flecainide induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107–111.
[5] Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141–150.[CrossRef][Web of Science][Medline]
[6] CAST investigators: Preliminary Report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412.[Abstract]
[7] Flaker GC, Blockshear JL, McBride R, Leroumal RA, Holferin JI, Hart RG. on behalf of the Stroke prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–532.[Abstract]
[8] Feld GK, Chen P-S, Nicod P, Fleck RP, Meyer D. Possible atrial proarrhythmic effects of Class IC antiarrhythmic drug. Am J Cardiol 1990; 66: 378–383.[CrossRef][Web of Science][Medline]
[9] Murdock CJ, Kyles AE, Yeung-Loi-Wah JA, Qi A, Vorderbrugge S, Kerr CR. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66: 755–757.[CrossRef][Web of Science][Medline]
[10] Brembilla-Perrot B and Terrier de la Chaise A. Provocation of supraventricular tachycardias by an intravenous Class I antiarrhythmic drug. Int J Cardiol 1992; 34: 189–198.[Medline]
[11] Tunick PA, McElhinney L, Mitchell T, Kronzai I. The alternation between atrial flutter and atrial fibrillation. Chest 1992; 101: 34–36.
[12] Lévy S, Novella P, Ricard P, Paganelli F. Paroxysmal atrial fibrillation: A need for classification. J Cardiovasc Electrophysiol 1995; 6: 69–74.[Web of Science][Medline]
[13] Waldo AL and MacLean WAH. Diagnosis and treatment of arrhythmias following open heart surgery: emphasis on the use of epicardial wire electrodes. 1980; Armonk; NY Futura Publishing Company.
[14] Watson RM and Josephson ME. Atrial flutter, 1: electrophysiologic substrate and modes of initiation and termination in humans. Circulation 1992; 86: 375–381.
[15] Allessie MA, Rensma PL, Brugada J, Smeets JLRM, Penn OC, Kirchhof CJMS. Pathophysiology of atrial fibrillation. In Zipes DP and Jalife J (Eds.). Cardiac electrophysiology: From cell to bedside 1990; Philadelphia WB Saunders Company pp. 548–58.
[16] Waldo AL. Mechanisms of atrial fibrillation, atrial flutter, and ectopic atrial tachycardia: a brief review. Circulation 1987; 75: 37–40.
[17] Ortiz J, Niwano S, Abe H, Rudy Y, Johnson NJ, Waldo AL. Mapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. Circ Res 1994; 75: 882–894.
[18] Pagé PL, Hassanalizadeh H, Cardinal R. Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dog with sterile pericarditis. Can J Physiol Pharmacol 1991; 69: 15–24.[Web of Science][Medline]
[19] Kingma JH and Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992; 70: 56A–60A.[CrossRef][Medline]
[20] Camm AJ, Ward D, Spurrell R. Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination. Br Heart J 1980; 44: 240–247.
[21] Waldo AL, MacLean WAH, Karp RB. Entrainment and interruption of atrial flutter with atrial pacing. Circulation 1977; 56: 737–745.
[22] Klein H and Werner PC. Atrial pacing in acute treatment of atrial flutter. In Waldo AL and Touboul P (Eds.). Atrial Flutter: Advances in mechanisms and management 1996; Armonk, NY Futura Publishing Company pp. 375–386.
[23] Della Bella P, Tondo C, Carbucicchio C, Riva S. The excitable gap of type I atrial flutter in humans. In Waldo AL and Touboul P (Eds.). Atrial flutter: advances in mechanisms and management 1996; Armonk, NY Futura Publishing Company pp. 259–268.
[24] Aliot E. Role of drugs to control atrioventricular conduction during atrial flutter. In Waldo AL and Touboul P (Eds.). Atrial flutter: advances in mechanisms and management 1996; Armonk, NY Futura Publishing Company pp. 363–368.
[25] Della Bella P, Carbucicchio C, Tondo C, Riva S. Modulation of the atrioventricular conduction by ablation of the ‘slow’ pathway in patients with drug refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25: 39–46.[Abstract]
[26] Della Bella P, Marenzi G, Tondo C. Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing. Am J Cardiol 1989; 63: 812–816.[CrossRef][Web of Science][Medline]
[27] Doni F, Della Bella P, Kheir A. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995; 76: 1243–1246.[CrossRef][Web of Science][Medline]
[28] Keane D, Sulke N, Cooke R, Jackson G, Sowton E. Endocardial cardioversion of atrial flutter and fibrillation (Abstr). PACE 1993; 16: 928.
[29] Murgatroyd FD and Camm AJ. Atrial arrhythmias: Who would be a candidate for an implantable atrial defibrillator? In Waldo AL and Touboul P (Eds.). Atrial flutter: advances in mechanisms and management 1996; Armonk, NY Futura Publishing Company pp. 427–438.
[30] Kalman JM, Olgin JE, Saxon LA, Lee RJ, Schienman MM, Lesh MD. Electrocardiographic and electrophysiologic characterization of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 1997; 8: 121–144.[Web of Science][Medline]
[31] Cosio FG, Lopez-Gil M, Goicolea A. Radiofrequency ablation of the inferior vena cava-tricuspid valve isthmus in common atrial flutter. Am J Cardiol 1993; 71: 705–709.[CrossRef][Web of Science][Medline]
[32] Fisher B, Haissaguerre M, Garrigues S. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25: 1365–1372.[Abstract]
[33] Lesh MD, Van Hare GF, Epstein LM. Radiofrequency catheter ablation of atrial arrhythmias – Results and mechanisms. Circulation 1994; 89: 1074–1089.
[34] Philippon F, Plumb VJ, Epstein AE, Kay GN. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. Circulation 1995; 92: 430–435.
[35] Saxon La, Kalman JM, Olgin JE, Sheinmann MM, Lee RJ, Lesh MD. Results of radiofrequency catheter ablation for atrial flutter. Am J Cardiol 1996; 77: 1014–1016.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Wolpert, K.K. Haase, T. Suselbeck, and M. Borggrefe Hybrid therapy for atrial fibrillation Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H51 - H55. [Abstract] [PDF]
|
|
|
|
 |
|
 P. D. Bella, A. Fraticelli, C. Tondo, S. Riva, G. Fassini, and C. Carbucicchio Atypical atrial flutter: clinical features, electrophysiological characteristics and response to radiofrequency catheter ablation Europace, January 1, 2002; 4(3): 241 - 253. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||